Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

NCT00111579 | Completed Phase 2

• 1 other identifier: MI-CP123
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 5

Brief Summary

The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.

Conditions

Influenza

Outcome Measures

Primary Outcomes (2)

• The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number

  Day 28 post final vaccination

• The proportion of participants achieving ≥ 4-fold increase in strain-specific HAI titer from baseline in all participants regardless of baseline serostatus, by dose number

  Day 28 post final vaccination

Secondary Outcomes (1)

• Safety endpoints include: AEs SAEs and significant new medical conditions for all participants

  Day 28 post vaccination

Study Arms (2)

1

ACTIVE COMPARATOR

CAIV-T

Biological: CAIV-T

2

OTHER

TIV

Other: TIV

Interventions

CAIV-T BIOLOGICAL

A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.

1

TIV OTHER

A total vol. of 0.25 will be administered intramuscularly for each of two doeses.

2

Eligibility Criteria

• Age: 6 Months - 36 Months
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Male or Female
• Ages 6 to but less than 36 months (reached their 6th month but have not yet reached their 3rd birthday) at the time of randomization
• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the participant's parent/legal representative
• Ability of the parent/legal representative to understand and comply with the requirements of the study
• Parent/legal representative available by telephone
• Ability to complete follow-up period of 180 days after final study vaccination, as required by the protocol

You may not qualify if:

• History of hypersensitivity to any component of CAIV-T or TIV, including egg or egg products, monosodium glutamate, porcine gelatin or thimerosal
• History of hypersensitivity to gentamicin
• Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
• Household contact who is immunocompromised (participants should also avoid close contact with immunocompromised individuals for at least 21 days after each study vaccination)
• History of Guillain-Barre syndrome
• Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled), by parent/legal representative report or chart review, within the 42 days prior to randomization (i.e., children with recent persistent asthma are excluded); or history of severe persistent asthma, according to the criteria described in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002
• Acute febrile (not greater than 100.0 degrees F oral or equivalent) and/or clinically significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to either study vaccination
• Use of aspirin or aspirin-containing products within 30 days prior to randomization, or expected use through 180 days after final study vaccination
• Receipt of any prior influenza vaccine
• Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to randomization, or expected use through 180 days after final study vaccination
• Administration of any live virus vaccine within 30 days prior to randomization, or expected receipt through 30 days after final study vaccination
• Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to randomization, or expected receipt within 14 days before, or 14 days after, either study vaccination
• Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 180 days after final study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
• Receipt of any blood product within 90 days prior to randomization, or expected receipt through 180 days after final study vaccination
• Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study

Sponsors & Collaborators

• MedImmune LLC: lead

Study Sites (5)

Wee Care Pediatrics

Layton, Utah, 84041, United States

Location

Bear Care Pediatrics

Ogden, Utah, 84405, United States

Location

Alpine Pediatrics

Pleasant Grove, Utah, 84062, United States

Location

Utah Valley Pediatrics

Provo, Utah, 84604, United States

Location

Families First Pediatrics

South Jordan, Utah, 84095, United States

Location

MeSH Terms

Conditions

Influenza, Human

Interventions

FluMist

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Study Officials

• Robert Walker, MD

  MedImmune LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: May 23, 2005
• First Posted: May 24, 2005
• Study Start: May 1, 2005
• Primary Completion: January 1, 2006
• Study Completion: January 1, 2006
• Last Updated: July 24, 2008

Record last verified: 2008-07

Locations

US (5)